Healwell AI (TSX: AIDX) is executing better than any other AI company. History will show that Hamed Shahbazi is the Elon Musk of AI and he is backed by some of the world's wealthiest investors including Li Ka-shing the wealthiest man in Hong Kong.
AIDX gained by 8.57% today to a new 52-week high of $1.90 per share.
AIDX is likely to become the next household name AI company later this month.
Axios released an article this morning about how 40% of all healthcare technology VC investments last quarter went into AI healthcare companies: click here to read!
AIDX is the only publicly traded AI healthcare pure play and its subsidiaries have developed several of the world's most advanced AI healthcare platforms! All private VC funded start-ups with equally advanced AI healthcare technology have already achieved implied valuations in the billions. Even newly formed AI healthcare start-ups that are nowhere close to achieving the recent AI healthcare breakthroughs of AIDX are already raising money at implied valuations of two, three, or four times the market cap of AIDX!
In recent days/weeks...
AIDX received validation in a landmark publication entitled, 'Real-world Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence'
AIDX implemented its AI technology with Toronto Public Health.
AIDX partnered with WELL Health USA’s CRH Medical to access U.S. clinical data to gain insights in supporting patients who are dealing with Inflammatory Bowel Disease and other gastrointestinal conditions. AIDX's Pentavere DARWEN™ AI platform will analyze over 200,000 US patients, in a secure and compliant manner across 21 states to understand the real-world dynamics between biologic prescribing and treatment outcomes.
AIDX integrated its proprietary Khure Health AI platform with Circle Medical’s electronic medical record system, expanding its footprint to over 30 US states to screen for and flag individual patients whom the healthcare practitioner might consider for further investigation for potential earlier diagnosis of rare disease.
AIDX has doubled its annual revenue run rate to over $20M while announcing it could soon double again to over $40M by using only its cash on hand to fuel this additional growth.
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA has received compensation from AIDX of US$50,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.
Preparing Americans for Hyperinflation
